2 days ago · Newly launched Newleos Therapeutics has secured $93.5 million in series A funds with a plan to develop four cast-off drugs from Roche’s neuropsychiatric division. All four drugs, now out-licensed to Boston-based Newleos, were put through at least Phase I clinical trials by Roche before being axed almost exactly one year ago in February 2024.

2 days ago · BOSTON, February 13, 2025--Newleos Therapeutics, Inc., a clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, today announced the closing ...

2 days ago · Newleos Therapeutics, Inc., a Boston, MA-based clinical stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, closed $93.5m Series A financing. The ...

2 days ago · Newleos Therapeutics debuted on Feb. 13, 2025, with $94 million and a plan to develop drugs for brain function and health. koto_feja via Getty Images A startup focused on brain drugs officially launched Thursday, backed by $94 million from a group of investors that includes one of the world’s largest banks and the parent company of Ozempic ...

1 day ago · Boston, USA-based Newleos Therapeutics, a neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, has announced its emergence and the closing of an oversubscribed $93.5 million Series A financing. Newleos’ clinical-stage pipeline was in-licensed from Swiss ...

1 day ago · Newleos Therapeutics has closed an oversubscribed Series A financing round, raising $93.5m to revolutionise neuropsychiatric disorder treatments with new medicines. Goldman Sachs Alternatives spearheaded the funding round which also saw contributions from Longwood Fund, Novo Holdings, Arkin Bio Ventures and DCVC Bio.

2 days ago · About Newleos Therapeutics, Inc. Newleos Therapeutics is dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in ...

2 days ago · Newleos Therapeutics Inc. was created by the Longwood Fund along with CNS drug developers Federico Bolognani and William Martin. The startup’s clinical-stage pipeline was licensed from Roche and ...

2 days ago · Newleos Therapeutics is dedicated to providing a new dawn or “eos” for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 ...

2 days ago · Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience treatments with several clinical programs from Swiss major Roche in hand.